Exact Sciences Co. (NASDAQ:EXAS) Receives $97.44 Consensus PT from Brokerages

Exact Sciences Co. (NASDAQ:EXAS) has earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $99.07.

Several equities research analysts have commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 22nd. Canaccord Genuity Group dropped their price objective on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Citigroup reaffirmed a “buy” rating and set a $100.00 price objective on shares of Exact Sciences in a report on Wednesday, April 3rd. Finally, TheStreet downgraded shares of Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $62.07 on Friday. Exact Sciences has a 1 year low of $56.05 and a 1 year high of $100.77. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07. The firm has a market cap of $11.41 billion, a price-to-earnings ratio of -54.45 and a beta of 1.26. The company has a fifty day moving average price of $63.37 and a 200-day moving average price of $64.72.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.26. The company had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.72) EPS. As a group, equities research analysts predict that Exact Sciences will post -0.86 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Jacob A. Orville sold 966 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $59,341.38. Following the transaction, the insider now directly owns 7,488 shares in the company, valued at $459,987.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Exact Sciences news, General Counsel James Herriott sold 415 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $25,522.50. Following the transaction, the general counsel now directly owns 6,943 shares in the company, valued at $426,994.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jacob A. Orville sold 966 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total transaction of $59,341.38. Following the transaction, the insider now owns 7,488 shares in the company, valued at $459,987.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 70,611 shares of company stock worth $4,255,377. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of EXAS. Wolff Wiese Magana LLC grew its position in Exact Sciences by 459.5% during the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 340 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Exact Sciences by 65.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 179 shares during the period. BluePath Capital Management LLC purchased a new stake in shares of Exact Sciences during the third quarter valued at approximately $33,000. Able Wealth Management LLC purchased a new stake in shares of Exact Sciences during the fourth quarter valued at approximately $45,000. Finally, Cullen Frost Bankers Inc. boosted its stake in shares of Exact Sciences by 40.0% during the third quarter. Cullen Frost Bankers Inc. now owns 700 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 200 shares during the period. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.